Cardiotoxicity is one of the main adverse effects of the anti-cancer drugs, affecting the completion of treatment and both short-term and long-term quality of life. Cardio-oncology is an emerging medical field involved in prevention, detection, and treatment of cardiovascular effects from cancer therapy.

Our lab, which is part of the European ERA-NET consortium in Cardio-Oncology, combines medicinal chemistry, molecular and cellular biology and pharmacology to address the following objectives:

- 1- to develop new cardioprotective non-peptide agonists of prokineticin receptor 1 (PKR1),

- 2- to discover novel prohibitins ligands and inhibitors of the initiation factor of translation eIF4A for the treatment of heart diseases and cancers,

- 3- to develop of novel diagnostic tools for cardiotoxicity,

- 4- to identify the molecular and cellular mechanisms controlling cardiac myogenesis, neovasculogenesis, and adipogenesis in hearts injured by anticancer drugs (anthracyclines, cisplatin, etc.).

The biological and medicinal chemistry studies are respectively supervised by Dr Canan Nebigil  and Dr Laurent Désaubry.

Contacts

Dr Canan Nebigil & Dr Laurent Désaubry, CNRS Research Directors, UMR 1260, INSERM-Université de Strasbourg,  Regenerative Nanomedicine, CRBS, 1 rue Eugène Boeckel, 67000 Strasbourg, France – Phone : (+33) 388 391 228- e-mails : nebigil@unistra.fr & desaubry@unistra.fr